PACAP is an endogenous protective factor-insights from PACAP-Deficient mice

Journal of Molecular Neuroscience

Volumn 48, Issue 3, 2012, Pages 482-492

  Reglodi, D ^a   Kiss, P ^a   Szabadfi, K ^a   Atlasz, T ^a   Gabriel, R ^a   Horvath, G ^a   Szakaly, P ^a   Sandor, B ^a   Lubics, A ^a   Laszlo, E ^a   Farkas, J ^a   Matkovits, A ^a   Brubel, R ^a   Hashimoto, H ^b   Ferencz, A ^c   Vincze, A ^a   Helyes, Z ^a   Welke, L ^d   Lakatos, A ^e   Tamas, A ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b OSAKA UNIVERSITY   (Japan)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytoprotective; Ischemia; Knockout; Protection

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 6;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; AXONAL INJURY; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL HYPOXIA; CELL LOSS; EXCITOTOXICITY; KIDNEY CELL CULTURE; METABOLIC STRESS; MICROSCOPY; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL DIFFERENTIATION; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NERVE INJURY; RETINA GANGLION CELL; RETINA ISCHEMIA; SPINAL CORD INJURY; TISSUE INJURY; TRAUMATIC BRAIN INJURY;

ANIMALS; AUTOIMMUNE DISEASES; CARDIOMYOPATHIES; DERMATITIS, ALLERGIC CONTACT; DISEASE SUSCEPTIBILITY; HOMEOSTASIS; INFLAMMATION; ISCHEMIA; KIDNEY DISEASES; LUNG DISEASES; MICE; MICE, KNOCKOUT; NERVOUS SYSTEM DISEASES; NEUROTOXINS; NOXAE; PANCREATIC DISEASES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; STRESS, PHYSIOLOGICAL; WOUNDS AND INJURIES;

MUS;

EID: 84868198185     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-012-9762-0     Document Type: Article

References (86)

1. Abad C, Waschek JA (2011) Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr Pharm Des 17:1025-1035
2. Ago Y, Yoneyama M, Ishihama T et al (2011) Role of endogenous pituitary adenylate cyclase-activating polypeptide in adult hippocampal neurogenesis. Neuroscience 172:554-561
3. Allais A, Burel D, Isaac ER et al (2007) Altered cerebellar development in mice lacking pituitary adenylate cyclase-activating polypeptide. Eur J Neurosci 25:2604-2618 (Pubitemid 46888850)
4. Alston EN, Parrish DC, Hasan W, Tharp K, Pahlmeyer L, Habecker BA (2011) Cardiac ischemia-reperfusion regulates sympathetic neuropeptide expression through gp130-dependent and independent mechanisms. Neuropeptides 45:33-42
5. Armstrong BD, Abad C, Chhith S et al (2008) Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience 151:63- 73
6. Atlasz T, Szabadfi K, Kiss P et al (2010) Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann NY Acad Sci 1200:128-139
7. Atlasz T, Babai N, Kiss P et al (2007) Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusioninduced retinal lesion in rats. Gen Comp Endocrinol 153:108- 114 (Pubitemid 47102321)
8. Azuma YT, Hagi K, Shintani N et al (2008) PACAP provides colonic protection against dextran sodium sulfate induced colitis. J Cell Physiol 216:111-119 (Pubitemid 351813101)
9. Botia B, Jolivel V, Burel D et al (2011) Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum. Neurotox Res 19:423-434
10. Chen Y, Samal B, Hamelink CR et al (2006) Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept 137:4-19 (Pubitemid 44751193)
11. Dejda A, Jolivel V, Bourgault S et al (2008) Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases. J Mol Neurosci 36:26-37
12. Dohi K, Mizushima H, Nakajo S et al (2002) Pituitary adenylate cyclase-activating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal transduction pathways. Regul Pept 109:83-88 (Pubitemid 35292398)
13. Elekes K, Sandor K, Moricz A et al (2011) Pituitary adenylate cyclaseactivating polypeptide plays an anti-inflammatory role in endotoxininduced airway inflammation: in vivo study with gene-deleted mice. Peptides 32:1439-1446
14. Endo K, Nakamachi T, Seki T et al (2011) Neuroprotective effect of PACAP against NMDA-induced retinal damage in the mouse. J Mol Neurosci 43:22-29
15. Ferencz A, Racz B, Tamas A et al (2009) Influence of PACAP on oxidative stress and tissue injury following small-bowel autotransplantation. J Mol Neurosci 37:168-176
16. Ferencz A, Kiss P, Gy Wet al (2010a) Comparison of intestinal warm ischemic injury in PACAP knockout and wild-type mice. J Mol Neurosci 42:435-442
17. Ferencz A, Gy W, Zs H, Hashimoto H, Baba A, Reglodi D (2010b) Presence of endogenous PACAP-38 ameliorated intestinal cold preservation tissue injury. J Mol Neurosci 42:428-434
18. Gasz B, Racz B, Roth E et al (2006) Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis. Peptides 27:87-94 (Pubitemid 43061041)
19. Gaszner B, Kormos V, Kozicz T, Hashimoto H, Reglodi D, Helyes Zs (2012) The behavioral phenotype of pituitary adenylate cyclaseactivating polypeptide deficient mice in anxiety and depression tests is accompanied by blunted c-Fos expression in the bed nucleus of the stria terminalis, central projecting Edinger Westphal nucleus, ventral lateral septum, and dorsal raphe nucleus. Neuroscience 202:283-299
20. Gray SL, Cummings KJ, Jirik FR, Sherwood NM (2001) Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol 15:1739-1747 (Pubitemid 32939304)
21. Hamelink C, Tjurmina O, Damadzic R et al (2002) Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci USA 99:461-466 (Pubitemid 34060383)
22. Hannibal J (2006) Roles of PACAP-containing retinal ganglion cells in circadian timing. Int Rev Cytol 251:1-39 (Pubitemid 44291412)
23. Hashimoto H, Shintani N, Tanaka K et al (2001) Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci USA 98:13355-13360 (Pubitemid 33051367)
24. Hashimoto H, Shintani N, Tanida M, Hayata A, Hashimoto R, Baba A (2011) PACAP is implicated in the stress axes. Curr Pharm Des 17:985-989
25. Hashimoto H, Hashimoto R, Shintani N et al (2009) Depression-like behavior in the forced swimming test in PACAP-deficient mice: amelioration by the atypical antipsychotic risperidone. J Neurochem 110:595-602
26. Hatanaka M, Tanida M, Shintani N et al (2008) Lack of light-induced elevation of renal sympathetic nerve activity and plasma corticosterone levels in PACAP-deficient mice. Neurosci Lett 444:153- 156
27. Horvath G, Mark L, Brubel R et al (2010a) Mice deficient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. Neurosci Lett 469:70-74
28. Horvath G, Racz B, Szakaly P et al (2010b) Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia. Transplant Proc 42:2293-2295
29. Isaac ER, Sherwood NM (2008) Pituitary adenylate cyclase-activating polypeptide (PACAP) is important for embryo implantation in mice. Mol Cell Endocrinol 280:13-19 (Pubitemid 350184197)
30. Kato H, Ito A, Kawanokuchi J et al (2004) Pituitary adenylate cyclase activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler 10:651-659 (Pubitemid 39585244)
31. Kawaguchi C, Tanaka K, Isojima Y et al (2003) Changes in lightinduced phase shift of circadian rhythm in mice lacking PACAP. Biochem Biophys Res Commun 310:169-175 (Pubitemid 37162778)
32. Kemeny A, Reglodi D, Cseharovszky R et al (2010) Pituitary adenylate cyclase-activating polypeptide deficiency enhances oxazoloneinduced allergic contact dermatitis in mice. J Mol Neurosci 42:443-449
33. Larsen JO, Hannibal J, Knudsen SM, Fahrenkrug J (1997) Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) in the mesencephalic trigeminal nucleus of the rat after transection of the masseteric nerve. Mol Brain Res 46:109-117 (Pubitemid 27214361)
34. Li M, Maderdrut JL, Lertora JJ, Arimura A, Batuman V (2008) Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. Regul Pept 145:24-32 (Pubitemid 350296365)
35. Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V(2011) Pituitary adenylate cyclase-activating polypeptide prevents cisplatin-induced renal failure. J Mol Neurosci 43:58-66
36. Mabuchi T, Shintani N, Matsumura S et al (2004) Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 24:7283-7291 (Pubitemid 39100698)
37. Markovics A, Kormos V, Gaszner B et al (2012) Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol- induced trigeminovascular activation in mice. Neurobiol Dis 45:633-644
38. Marquez P, Bebawy D, Lelievre V et al (2009) The role of endogenous PACAP in motor stimulation and conditioned place preference induced by morphine in mice. Psychopharmacology 204:457-463
39. Mester L, Szabo A, Atlasz T et al (2009) Protection against chronic hypoperfusion-induced retinal neurodegeneration by PARP inhibition via activation of PI3-kinase Akt pathway and suppression of JNK and p38 MAP kinases. Neurotox Res 16:68-76
40. Miyata A, Arimura A, Dahl RR et al (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567- 574 (Pubitemid 19269770)
41. Moller K, Reimer M, Ekblad E et al (1997) The effects of axotomy and preganglionic denervation on the expression of pituitary adenylate cyclase activating polypeptide (PACAP), galanin and PACAP type 1 receptors in the rat superior cervical ganglion. Brain Res 775:166-182 (Pubitemid 28020501)
42. Mori H, Nakamachi T, Ohtaki H et al (2010) Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on doxorubicin-induced cardiomyopathy in mice. Circ J 74:1183- 1190
43. Nakamachi T, Farkas J, Watanabe J et al (2011) Role of PACAP in neural stem/progenitor cell and astrocyte - from neural development to neural repair. Curr Pharm Des 17:973-984
44. Nakamachi T, Ohtaki H, Yofu S et al (2010) Endogenous pituitary adenylate cyclase activating polypeptide is involved in suppression of edema in the ischemic brain. Acta Neurochir Suppl 106:43-46
45. Nakata M, Shintani N, Hashimoto H, Baba A (2010) Intra-islet PACAP protects pancreatic beta-cells against glucotoxicity and lipotoicity. J Mol Neurosci 42:404-410
46. Nemetz N, Abad C, Lawson G et al (2008) Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP. Int J Cancer 122:1803-1809 (Pubitemid 351413427)
47. Ogawa T, Nakamachi T, Ohtaki H et al (2005) Monoaminergic neuronal development is not affected in PACAP-gene-deficient mice. Regul Pept 126:103-108 (Pubitemid 40037751)
48. Ohtaki H, Nakamachi T, Dohi K et al (2006) Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci USA 103:7488-7493 (Pubitemid 43727860)
49. Ohtaki H, Nakamachi T, Dohi K, Shioda S (2008) Role of PACAP in ischemic neural death. J Mol Neurosci 36:16-25
50. Ohtaki H, Satoh A, Nakamachi T et al (2010) Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor. J Mol Neurosci 42: 397-403
51. Onoue S, Hanato J, Yamada S (2008) Pituitary adenylate cyclaseactivating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression. FEBS J 275:5542-5551
52. Pinhasov A, Nesher E, Gross M, Turgeman G, Kreinin A, Yadid G (2011) The role of the PACAP signaling system in depression. Curr Pharm Des 17:990-1001
53. Racz B, Gasz B, Gallyas F et al (2008) PKA-Bad-14-3-3 and Akt-Bad- 14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia/reperfusion-induced cardiomyocyte apoptosis. Regul Pept 145:105-115 (Pubitemid 350296368)
54. Racz B, Reglodi D, Horvath G et al (2010) Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture. J Mol Neurosci 42:419-427
55. Reglodi D, Tamas A, Somogyvari-Vigh A et al (2002) Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 23:2227- 2234 (Pubitemid 36092058)
56. Reglodi D, Kiss P, Lubics A, Tamas A (2011) Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des 17:962-972
57. Reglodi D, Kiss P, Horvath G et al (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 46:61-70
58. Riek-Burchardt M, Kolodziej A, Henrich-Noack P, Reymann KG, Hollt V, Stumm R (2010) Differential regulation of CXCL12 and PACAP mRNA expression after focal and global ischemia. Neuropharmacology 58:199-207
59. Sakurai Y, Shintani N, Hayata A, Hashimoto H, Baba A (2011a) Trophic effects of PACAP on pancreatic islets: a mini-review. J Mol Neurosci 43:3-7
60. Sakurai Y, Shintani N, Arimori A et al (2011b) Cerulein-induced acute pancreatitis in PACAP knockout mice. J Mol Neurosci 43:8-15
61. Sandor K, Kormos V, Botz B et al (2010) Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice. Neuropeptides 44:363-371
62. Sano H, Miyata A, Horio T, Nishikimi T, Matsuo H, Kangawa K (2002) The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor. Regul Pept 109:107-113 (Pubitemid 35292401)
63. Seaborn T, Masmoudi-Kouli O, Fournier A, Vaudry H, Vaudry D (2011) Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. Curr Pharm Des 17:204- 214
64. Shin CM, Chung YH, Kim MJ, Cha CI (2001) Spatial and temporal distribution of pituitary adenylate cyclase activating polypeptide in gerbil global cerebral ischemia. Neurosci Lett 309:53-56 (Pubitemid 32728258)
65. Shintani N, Mori W, Hashimoto H et al (2002) Defects in reproductive functions in PACAP-deficient female mice. Regul Pept 109:45-48 (Pubitemid 35292392)
66. Skoglosa Y, Lewen A, Takei N, Hillered L, Lindholm D (1999) Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type I after traumatic brain injury: comparison with brain-derived neurotrophic factor and the induction of neuronal cell death. Neuroscience 90:235-247 (Pubitemid 29096469)
67. Somogyvari-Vigh A, Reglodi D (2004) Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 10:2861-2689
68. Stroth N, Holighaus Y, Ait-Ali D, Eiden LE (2011) PACAP: a master regulator of neuroendocrine stress circuits and the cellular stress response. Ann NY Acad Sci 1220:49-59
69. Stumm R, Kolodziej A, Prinz V, Endres M, Wu DF, Hollt V (2007) Pituitary adenylate cyclase activating polypeptide is up-regulated in cortical pyramidal cells after focal cerebral ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem 103:1666-1681 (Pubitemid 47631830)
70. Szabadfi K, Atlasz T, Kiss P et al (2012) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox Res 21:41-48
71. Szakaly P,Kiss P, LubicsAet al (2008) Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion. J Mol Neurosci 36:89-96
72. Szakaly P, Laszlo E, Kovacs K et al (2011) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury. Neuropeptides 45:113-121
73. TamasA, Reglodi D, Szanto Z, Borsiczky B,Nemeth J, Lengvari I (2002) Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats. Neuroendocrinol Lett 23:249-254 (Pubitemid 34741935)
74. Tamas A, Szabadfi K, Nemeth A et al (2012) Comparative examination of inner ear in wild type and pituitary adenylate cyclase activating polypeptide (PACAP)-deficient mice. Neurotox Res 21:435-444
75. Tan YV, Abad C, Lopez R et al (2009) Pituitary adenylyl cyclase activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 106:2012-2017
76. Tanaka K, Hashimoto H, Shintani N, Yamamoto A, Baba A (2004) Reduced hypothermic and hypnotic responses to ethanol in PACAP-deficient mice. Regul Pept 123:95-98 (Pubitemid 39424154)
77. Tomimoto S, Ojika T, Shintani N et al (2008) Markedly reduced white adipose tissue and increased insulin sensitivity in Adcyap1-deficient mice. J Pharmacol Sci 107:41-48 (Pubitemid 351760826)
78. Tsuchikawa D, Nakamachi T, Tsuchida M, Wada Y et al (2011) The neuroprotective effect of endogenous PACAP on spinal cord injury. Abstract. Presented at the 10th international Symposiumson VIP, PACAP and related peptides, 2011
79. Eilat, Israel Vaudry D, Hamelink C, Damadzic R, Eskay RL, Gonzalez B, Eiden LE (2005) Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides 26:2518-2524 (Pubitemid 41676726)
80. Vaudry D, Falluel-Morel A, Bourgault A et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharm Rev 61:283-357
81. Vincze A, Reglodi D, Zs H,HashimotoH, Shintani H, AbrahamH (2011) Role of pituitary adenylate cyclase activating polypeptide (PACAP) in myelination of the rodent brain: lessons from PACAP-deficient mice. Int J Dev Neurosci 29:923-935
82. Wilson RJ, Cummings KJ (2008) Pituitary adenylate cyclase-activating polypeptide is vital foe neonatal survival and the neuronal control of breathing. Respir Physiol Neurobiol 164:168-178
83. Yamada K, Matsuzaki S, Hattori T et al (2010) Increased stathmin1 expression in the dentate gyrus of mice causes abnormal axonal arborizations. PLoS One 5:e8596
84. Zhang YZ, Hannibal J, Zhao Q et al (1996) Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: upregulation after peripheral nerve injury. Neuroscience 74:1099- 1110 (Pubitemid 26313353)
85. Zhang Y, Danielsen N, Sundler F, Mulder H (1998) Pituitary adenylate cyclase-activating peptide is upregulated in sensory neurons by inflammation. Neuroreport 9:2833-2836 (Pubitemid 28435172)
86. Zhou X, Rodriguez WI, Casillas RA et al (1999) Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus. J Neurosci Res 57:953-961 (Pubitemid 29416126)